Literature DB >> 7478607

Identification and functional characterization of the human and murine polo-like kinase (Plk) promoter.

A Bräuninger1, K Strebhardt, H Rübsamen-Waigmann.   

Abstract

The Plk gene encodes a serine/theronine kinase which is located in the nucleus. Northern blot analysis linked Plk expression to the proliferative activity of cells and tissues. To analyse the transcriptional regulation of the Plk gene we have isolated several human genomic clones containing the Plk promoter. RNAse protection assays revealed three major transcription start sites within a 40 bp region centered around the 5' end of the known human cDNA and 6 minor Cap sites. A genomic fragment of 2.3 kb located 5' to the translation start sites drives the expression of the CAT-reporter in transient transfections in human (EPLC, HeLa) and mouse (NIH3T3, 32D) cell lines in an orientation dependent fashion. The 2.3 kb genomic fragment contains a CCAAT motif located 30-70 bp upstream of the Cap sites and two overlapping Sp1 sites 20 bp further upstream. Additional sequence motif homologues to binding sites of known transcription factors could be identified. In addition to the human Plk promoter, the mouse Plk promoter was isolated. The sequence alignment of the human and murine promoter revealed three regions with extensive sequence homology within a region of 300 bp immediately upstream of the Cap sites. A fourth region of homology encompassing 90 bp about 2.1 kb 5' of the Cap sites was identified as well. Deletion of various regions within the 2.3 kb promoter fragment identified several domains involved in the regulation of the human Plk promoter. The 300 bp region immediately 5' of the Cap sites which is highly conserved between mouse and man is essential for promoter activity. 3' deletions including the CCAAT site abolished promoter activity. Growing 5' deletions within the core region of the promoter reduces transcriptional activity. Furthermore, using deletion clones we identified regions 5' of the core region which enhance or silence the transcriptional activity of the core promoter.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7478607

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  6 in total

1.  KDM4/JMJD2 Histone Demethylase Inhibitors Block Prostate Tumor Growth by Suppressing the Expression of AR and BMYB-Regulated Genes.

Authors:  Lingling Duan; Ganesha Rai; Carlos Roggero; Qing-Jun Zhang; Qun Wei; Shi Hong Ma; Yunyun Zhou; John Santoyo; Elisabeth D Martinez; Guanghua Xiao; Ganesh V Raj; Ajit Jadhav; Anton Simeonov; David J Maloney; Josep Rizo; Jer-Tsong Hsieh; Zhi-Ping Liu
Journal:  Chem Biol       Date:  2015-09-10

2.  Polo-like kinase, a novel marker for cellular proliferation.

Authors:  J Yuan; A Hörlin; B Hock; H J Stutte; H Rübsamen-Waigmann; K Strebhardt
Journal:  Am J Pathol       Date:  1997-04       Impact factor: 4.307

3.  A 3'UTR polymorphism modulates mRNA stability of the oncogene and drug target Polo-like Kinase 1.

Authors:  Neval Akdeli; Kathrin Riemann; Jana Westphal; Jochen Hess; Winfried Siffert; Hagen S Bachmann
Journal:  Mol Cancer       Date:  2014-04-26       Impact factor: 27.401

4.  Association of p21 with NF-YA suppresses the expression of Polo-like kinase 1 and prevents mitotic death in response to DNA damage.

Authors:  Y-C Lin; Y-N Chen; K-F Lin; F-F Wang; T-Y Chou; M-Y Chen
Journal:  Cell Death Dis       Date:  2014-01-09       Impact factor: 8.469

5.  Mechanisms of transcriptional repression of cell-cycle G2/M promoters by p63.

Authors:  Barbara Testoni; Roberto Mantovani
Journal:  Nucleic Acids Res       Date:  2006-02-09       Impact factor: 16.971

Review 6.  Battle of the eternal rivals: restoring functional p53 and inhibiting Polo-like kinase 1 as cancer therapy.

Authors:  Frank Louwen; Juping Yuan
Journal:  Oncotarget       Date:  2013-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.